It is understandable that shareholders are frustrated as the SP is well down from the highs of 18 months ago. Biotech is an industry where it doesn’t pay to rush. You need to be methodical about how you go about things or else you will just run into problems later with the regulators. There have been quite a few disasters on the ASX where biotechs have rushed only to have their program blow up later.
Everyone can assume that me joining the RAC board and taking on the responsibility of being the CSO will have a significant effect on the direction and focus of RAC - if I didn’t then I shouldn’t (and wouldn’t) be there. When things do change the shareholders will be kept informed as is our responsibility under the ASX continuous disclosure rules.
RAC Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)